Debut Plus

₹19.9

▼ -0.6 -2.93%

As of 23 Oct 2026 · delayed

NSE Listed

Medico Remedies Limited (MEDICO)

Volume: 1,57,783Avg Vol 1W: 1,43,288Avg Vol 1M: 6,54,278.552W Range:₹19.11₹56.88
Market Cap₹165 Cr
Current Price₹19.9
Previous Close₹20.5
High / Low (52w)₹56.88 / ₹19.11
Volume1,57,783
Avg Vol (1W)1,43,288
Avg Vol (1M)6,54,278.5
Stock P/E11.99
Book Value₹9.1
Dividend Yield0%
ROE17.38%
ROA9.01%
Revenue (TTM)₹212 Cr
Revenue Growth—
Profit Margin5.82%
Total Debt—
Shares Outstanding8 Cr
Face Value₹2
EPS (TTM)₹1.66
P/B2.22
Debt / Equity0.24
50 DMA₹32.96
200 DMA₹40.61
Day change-2.93%
Price Chart
₹19.9▼ 60.00% · 1Y
₹55₹2048.4L
2025-10-27
2026-10-23

20-day avg volume: 6.5L shares

Pros
  • Healthy return on equity of 17.4%.
  • Company is almost debt-free.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹39 Cr₹39 Cr₹41 Cr₹38 Cr₹53 Cr₹59 Cr₹57 Cr₹69 Cr
EBITDA₹2 Cr₹4 Cr₹6 Cr₹3 Cr₹4 Cr₹4 Cr₹9 Cr₹4 Cr
Net Profit₹2 Cr₹3 Cr₹4 Cr₹2 Cr₹3 Cr₹3 Cr₹6 Cr₹3 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹100 Cr₹91 Cr₹123 Cr₹123 Cr₹144 Cr₹147 Cr₹154 Cr₹212 Cr
EBITDA₹3 Cr₹3 Cr₹5 Cr₹7 Cr₹11 Cr₹12 Cr₹15 Cr₹20 Cr
Net Profit₹2 Cr₹2 Cr₹3 Cr₹5 Cr₹7 Cr₹8 Cr₹10 Cr₹13 Cr
EPS3.783.931.560.580.8711.221.58
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹76 Cr₹75 Cr₹76 Cr₹77 Cr₹87 Cr₹96 Cr₹120 Cr₹153 Cr
Total Liabilities₹48 Cr₹45 Cr₹43 Cr₹41 Cr₹44 Cr₹44 Cr₹57 Cr₹78 Cr
Equity₹28 Cr₹30 Cr₹32 Cr₹37 Cr₹44 Cr₹52 Cr₹62 Cr₹75 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-10 Cr₹8 Cr₹11 Cr₹6 Cr₹9 Cr₹11 Cr
Investing₹-17 Cr₹-2 Cr₹-7 Cr₹-3 Cr₹-3 Cr₹-5 Cr
Financing₹18 Cr₹-6 Cr₹-2 Cr₹0 Cr₹-1 Cr₹-1 Cr
Free Cash Flow₹-10 Cr₹8 Cr₹11 Cr₹6 Cr₹9 Cr₹11 Cr
Shareholding
Promoter 61.38% Institutions 0.6% Public 38.02%
About Medico Remedies Limited

Healthcare · Drug Manufacturers - Specialty & Generic

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.

medicoremedies.com ↗
Efficiency & Working Capital
ROCE21%
Interest Coverage11
Dividend Payout—
Debtor Days145 d
Inventory Days53 d
Payable Days87 d
Cash Conversion Cycle111 d
Working Capital Days198 d
Shareholding Details

As of 2026-09-30

Promoter61.4%
FII0.6%
DII0%
Institutions0.6%
Public38%
Promoter Pledge0%
No. of Shareholders17,716
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Promoters73.3%73.3%73.3%73.3%66.8%63.8%62.6%61.4%61.4%61.4%61.4%61.4%
FIIs1.3%0.3%0.2%0.2%0.4%0.1%0.1%0.3%0.5%0%0.1%0.6%
DIIs0%0.7%1%1%0.8%0%0%0%0%0%0%0%
Public25.4%25.6%25.5%25.5%32%36.1%37.3%38.3%38.1%38.6%38.5%38%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders6,05210,68512,90212,88714,10415,42416,47418,50316,56216,18915,86317,716
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Haresh Kapurlal MehtaShareholding of Promoter and Promoter Group20.2%1.68 Cr
Mehta Rishit HareshbhaiShareholding of Promoter and Promoter Group12.7%1.05 Cr
Harshit Haresh MehtaShareholding of Promoter and Promoter Group10.4%86,20,000
Rita H MehtaShareholding of Promoter and Promoter Group8.1%66,78,000
Shweta Harshit MehtaShareholding of Promoter and Promoter Group5.9%48,82,170
Priyal Rishit MehtaShareholding of Promoter and Promoter Group4.2%34,77,775
Haresh K Mehta HufShareholding of Promoter and Promoter Group0%0
Harshit H Mehta HufShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Haresh MehtaChairman & Executive Director & CFO2025
Harshit MehtaED / MD / Promoter2025
Rishit MehtaE D & Wholetime Director2025
Rita MehtaNon-Exec & Non-Independent Dir2025
Deepak VekariaIndependent Non Exe. Director2025
Bharat RathodIndependent Non Exe. Director2025
Deepesh Rajesh ShahIndependent Non Exe. Director2025
Kunal VoraIndependent Non Exe. Director2025
Anuj Kishore ModyIndependent Non Exe. Director2025
Maheshkumar DarjiIndependent Non Exe. Director2025
Vidhi Ankit ShahCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacturers of Pharmaceutical For₹0 Cr—
Segments — Geography
RegionRevenueShare
India₹7 Cr13.6%
Outside India₹45 Cr86.4%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹2171717
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-13Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026000506
2026000303
2026000203
Insider / Designated-Person Trades

13 recent disclosure(s)

Shweta Harshit MehtaDisposal · 2,00,000
Harshit H Mehta HUFDisposal · 2,50,000
Harshit H Mehta HUFDisposal · 4,00,000
Rishit Haresh MehtaDisposal · 14,00,000
Rishit Haresh MehtaDisposal · 4,00,000
Shweta Harshit MehtaDisposal · 9,00,000
Substantial Acquisitions (SAST)

2 disclosure(s)

Market24/09/2025 - 25/09/2025 · 5,00,000
Market24/09/2025 - 25/09/2025 · 5,00,000
Company Information
Incorporated1994
ChairmanHaresh Mehta
AuditorShah Shroff & Associates
Investor Email[email protected]
🌐 www.medicoremedies.com ↗

📍 1105/1106 11-Flr Hubtown Solar, N S Phadke Marg Andheri East, Mumbai, Maharashtra, 400069

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search